Home » Stocks » ADXN

Addex Therapeutics Ltd. (ADXN)

Stock Price: $12.12 USD -0.82 (-6.34%)
Updated Jan 22, 2021 4:00 PM EST - Market closed
Pre-market: $11.12 -1.00 (-8.25%) Jan 25, 5:18 AM
Market Cap 68.27M
Revenue (ttm) 2.85M
Net Income (ttm) -15.24M
Shares Out 32.85M
EPS (ttm) -0.58
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day January 22
Last Price $12.12
Previous Close $12.94
Change ($) -0.82
Change (%) -6.34%
Day's Open 12.39
Day's Range 11.52 - 12.45
Day's Volume 295,005
52-Week Range 6.19 - 21.00

News

Hide News
Benzinga - 3 days ago

Genetic Technologies (NASDAQ: GENE) shares are trading higher after the company provided an update on its COVID-19 severity risk test, saying predictive capabilities improved 100% over age and...

Other stocks mentioned: OBLN, GENE
InvestorPlace - 3 days ago

Addex Therapeutics (ADXN) stock is soaring higher on Thursday after announcing news concerning a clinical trial for its epilepsy drug. The post Epilepsy Drug News: Why Addex Therapeutics (ADXN...

GlobeNewsWire - 2 weeks ago

Geneva, Switzerland, January 7, 2021 – Addex Therapeutics Ltd (SIX: ADXN and Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and de...

About ADXN

Addex Therapeutics Ltd, a development-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule pharmaceutical products for central nervous system (CNS) disorders in Switzerland. The company focuses on the discovery of oral small molecule allosteric modulators of G-protein coupled receptors. Its lead programs include Dipraglurant for the treatment of Parkinson's disease levodopa-induced dyskinesia, and dystonia; ADX71149 for epilepsy and undisclosed CNS disorders; and GABAB PAM for addiction. It has license and col... [Read more...]

Industry
Pharmaceutical Preparation Manufacturing
Founded
2002
CEO
Tim Dyer
Employees
19
Stock Exchange
NASDAQ
Ticker Symbol
ADXN
Full Company Profile

Financial Performance

In 2019, ADXN's revenue was 2.76 million, a decrease of -54.29% compared to the previous year's 6.04 million. Losses were -14.78 million, 798.6% more than in 2018.

Financial numbers in millions CHF.
Financial Statements